“GLP-1s give you diabetes.”
What the evidence shows
GLP-1 receptor agonists are, first and foremost, FDA-approved treatments for type 2 diabetes — they lower blood sugar. In obesity trials of people with prediabetes, they also reduced progression to type 2 diabetes rather than causing it. The direction of effect is the opposite of the claim.
What we still don’t know
Like any glucose-lowering context, blood sugar has to be managed sensibly — for example, the risk of low blood sugar rises if a GLP-1 is combined with insulin or a sulfonylurea, which is a dosing conversation with a prescriber. But that's about managing lows, not the drug causing diabetes.
Why the claim misleads
This one likely stems from confusing correlation with cause (people prescribed these drugs often already have, or are at risk for, diabetes) or from garbled reporting. The evidence is clear and consistent: GLP-1s treat and help prevent type 2 diabetes; they do not cause it.
Graded by The Peptide Era · evidence, not hype